IMRN ▲ +9.9% - Immuron Limited $IMRN - Immuron to launch PROIBS® in the United States Immuron Limited shares rose 9.9% today following the company's announcement that it will launch PROIBS®, its immunoglobulin-based therapeutic, in the United States. The U.S. market entry represents a significant expansion opportunity for the company's gastrointestinal health product line. 04-SEP-2026 06:00 AM ET